Gossamer Bio, Inc. (NASDAQ:GOSS) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Gossamer Bio, Inc. (NASDAQ:GOSS) have earned a consensus recommendation of “Moderate Buy” from the seven research firms that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation and six have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $8.60.

A number of equities research analysts have issued reports on GOSS shares. Barclays started coverage on shares of Gossamer Bio in a research note on Tuesday, January 27th. They set an “overweight” rating and a $9.00 target price for the company. HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Gossamer Bio in a research note on Thursday, January 22nd. Wall Street Zen lowered Gossamer Bio from a “hold” rating to a “sell” rating in a research report on Friday, January 23rd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Gossamer Bio in a report on Thursday, January 22nd.

Hedge Funds Weigh In On Gossamer Bio

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its position in Gossamer Bio by 5.2% during the 3rd quarter. Vanguard Group Inc. now owns 12,009,773 shares of the company’s stock worth $31,586,000 after acquiring an additional 598,981 shares during the last quarter. Acadian Asset Management LLC lifted its position in shares of Gossamer Bio by 12.4% during the 2nd quarter. Acadian Asset Management LLC now owns 7,146,022 shares of the company’s stock worth $8,786,000 after purchasing an additional 787,909 shares during the last quarter. Geode Capital Management LLC boosted its stake in Gossamer Bio by 100.4% during the 2nd quarter. Geode Capital Management LLC now owns 4,555,080 shares of the company’s stock valued at $5,604,000 after purchasing an additional 2,282,632 shares during the period. Corient Private Wealth LLC boosted its stake in Gossamer Bio by 8.9% during the 2nd quarter. Corient Private Wealth LLC now owns 3,693,683 shares of the company’s stock valued at $4,543,000 after purchasing an additional 302,200 shares during the period. Finally, Millennium Management LLC grew its holdings in Gossamer Bio by 629.3% in the 3rd quarter. Millennium Management LLC now owns 3,619,329 shares of the company’s stock valued at $9,519,000 after buying an additional 3,123,081 shares during the last quarter. Institutional investors and hedge funds own 81.23% of the company’s stock.

Gossamer Bio Trading Down 7.0%

GOSS stock opened at $2.26 on Friday. Gossamer Bio has a one year low of $0.76 and a one year high of $3.87. The firm has a 50-day moving average of $2.96 and a two-hundred day moving average of $2.66. The firm has a market capitalization of $523.10 million, a PE ratio of -3.28 and a beta of 1.93.

Gossamer Bio (NASDAQ:GOSS) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). The business had revenue of $13.29 million for the quarter, compared to analysts’ expectations of $6.32 million. Gossamer Bio had a negative net margin of 354.50% and a negative return on equity of 1,774.72%. On average, equities research analysts anticipate that Gossamer Bio will post -0.28 earnings per share for the current year.

Gossamer Bio Company Profile

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.